| Zecuity (transdermal sumatriptan) / Teva |
NCT00546650: Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex® |
|
|
| Completed | 1 | 25 | US | Sumatriptan succinate | NuPathe Inc. | Healthy | 12/07 | 03/08 | | |
NP101-006, NCT00720018: Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers |
|
|
| Completed | 1 | 4 | US | NP101 Sumatriptan Iontophoretic Transdermal Patch | NuPathe Inc. | Migraine Disorders | 07/08 | 07/08 | | |
NP101-011, NCT00723983: Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period |
|
|
| Completed | 1 | 23 | US | Sumatriptan succinate, NP101 Study Patch | NuPathe Inc. | Migraine Disorders | 09/09 | 09/09 | | |
NCT01381796: Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults |
|
|
| Completed | 1 | 63 | US | NP101, sumatriptan succinate, Imitrex | NuPathe Inc. | Compare Bioequivalence Patches Previously Used in the NP101-007 Study | 09/10 | 09/10 | | |
NCT02684409: Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine |
|
|
| Completed | 1 | 37 | US | PROT-CL-NP101-015.01, Zecuity®, Sumatriptan | NuPathe Inc. | Acute Migraine | 11/14 | 11/14 | | |
NCT06217094: Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment |
|
|
| Not yet recruiting | 1 | 18 | NA | NP-101 (3 g), NP-101 (4.8 g), NP-101 (6 g) | University of Florida, Novatek | Hepatocellular Carcinoma | 07/26 | 09/29 | | |
